The MEDMAN study: A randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease

Family Practice

Volumn 24, Issue 2, 2007, Pages 189-200

  Bond, Christine ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Clinical outcomes; Community pharmacy; Coronary heart disease; RCT

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; WARFARIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; ECONOMIC EVALUATION; FEMALE; FOLLOW UP; GENERAL PRACTICE; GENERAL PRACTITIONER; HEALTH CARE COST; HEALTH STATUS; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NATIONAL HEALTH SERVICE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHARMACEUTICAL CARE; PHARMACIST; PHARMACY; PRESCRIPTION; PROFESSIONAL PRACTICE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SHORT FORM 36; SOCIAL ASPECT; SOCIAL SUPPORT; TREATMENT DURATION; UNITED KINGDOM; CORONARY ARTERY ATHEROSCLEROSIS; HOSPITAL ORGANIZATION; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PROFESSIONAL STANDARD; QUESTIONNAIRE;

AGED; COMMUNITY PHARMACY SERVICES; CORONARY ARTERIOSCLEROSIS; ENGLAND; FEMALE; HEALTH STATUS; HUMANS; MALE; MEDICATION SYSTEMS; MIDDLE AGED; PHARMACISTS; PROFESSIONAL ROLE; QUESTIONNAIRES;

EID: 34248356865     PISSN: 02632136     EISSN: 14602229     Source Type: Journal    
DOI: 10.1093/fampra/cml075     Document Type: Article

References (37)

1. ISD standardised mortality rates. http://www.heartstats.org/ (accessed on January 3, 2007).
2. Hourihan F, Krass I, Chen T, Coper L. Rural community pharmacy: A feasible site for a health promotion and screening service for cardiovascular risk factors. Aust J Rural Health 2003; 11: 28-35.
3. Moher M. Managing established heart disease. Br Med J 1997; 317 69-70.
4. Sacks FM, Pfeffer MA, Moye LA et al. The effect of prevastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: A randomised placebo-controlled trial. Lancet North Am Ed 2002; 360: 7-22.
6. Campbell NC, Thain J, Deans HG, Ritchie LD, Rawles JM, Squair JL. Secondary prevention clinics for coronary heart disease: Randomised trial of effect on health. Br Med J 1998; 316: 1434-1437.
7. Murchie P, Campbell NC, Ritchie LD, Simpson JA, Thain J. Secondary prevention clinics for coronary heart disease: Four year follow up of a randomised controlled trial in primary care. Br Med J 2003; 326 84.
8. Simpson CR, Hannaford PC, Williams D. Evidence for inequalities in the management of coronary heart disease in Scotland. Heart 2005; 91: 630-634.
9. Implementing the new Community Pharmacy Contractual Framework http://www.dh.gov.uk/PolicyAndGuidance/MedicinesPharmacyAndIndustry/ CommunityPharmacyContractualFramework/fs/en (accessed on January 3, 2007).
10. Watson M, Bond C, Matheson C, Taylor A. Community pharmacists and medicine management for patients with coronary heart disease: A comprehensive literature review; 1998.
11. Blenkinsopp A, Phelan M, Bourne J, Dakhil N. Extended adherence support by community pharmacists for patients with hypertension: A randomised controlled trial. Int J Pharm Pract 2000; 8 (3): 165-175.
12. Park JJ, Kelly P, Carter BL et al. Comprehensive pharmaceutical care in the chain setting. J Am Pharm Assoc 1996; NS36 (7): 443-451.
13. Gardner S, Skelton D, Rollins S et al. Community pharmacy databases to identify patients at high risk for hypercholesterolaemia. Pharmacotherapy 1995; 15 (3): 292-296.
14. Hall J, Radley A, John S. Community and hospital pharmacist cooperation in an outreach anticoagulant clinic. Pharm J 1995; 255 (suppl) R24.
15. Blenkinsopp A, Anderson C, Armstrong M. Systematic review of the effectiveness of community pharmacy-based interventions to reduce risk behaviours and risk factors for coronary heart disease. J Public Health Med 2003; 25 (92): 144-153.
16. Maguire TA, McElnay JC, Drummond A. A randomised controlled trial of a smoking cessation intervention based in community pharmacies. Addiction 2001; 96 (2): 325-331.
17. Sinclair H, Bond C, Lennox A et al. Training pharmacists and pharmacy assistants in the stage-of-change model of smoking cessation: A randomised controlled trial in Scotland. Tob Control 1998; 7 253-261.
18. National Service Framework (NSF) for coronary heart disease. http://www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialCareTopics/ CoronaryHeartDisease/fs/en (accessed on January 3, 2007).
19. SF 36. http://www.sf-36.org. (accessed on January 3, 2007).
20. Kind P. The EuroQol instrument: An index of health related quality of life. In: Spiker B (ed.). Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd edn. Philadelphia: Lippincott-Raven; 1996: 191-200.
21. Pocock SJ, McCormack V, Gueffier F. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. Br Med J 2001; 323: 75-81.
22. Bennett M. A Risk Score for Cardiovascular Disease. http://www.riskscore.org.uk/index.html (accessed on January 3, 2007).
23. Hooper H, Blenkinsopp A. Measurement of patient satisfaction with pharmaceutical services: Literature review 2002.
24. Heckman J. Sample selection bias as a specification error. Econometrica 1979; 47: 153-161.
25. Holland R, Lenaghan E, Harvey I et al. Does home based medication review keep older people out of hospital? The HOMER randomised controlled trial. Br Med J 2005; 330: 293.
26. Nola K, Gourley D, Portner T. Clinical and humanistic outcomes of a lipid management programme in the community pharmacy setting. J Am Pharm Assoc 2000; 40: 166-173.
27. Tsuyuki RT, Johnson JA, Teo KK et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: The Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med 2002; 162 (10): 1149-1155.
28. New GMS contract. http://www.equip.ac.uk/newContract/docs/ GP_Contract.pdf (accessed on January 3, 2007).
29. Quality and Outcomes Framework information. http://www.dh.gov.uk/ PolicyAndGuidance/OrganisationPolicy/PrimaryCare/PrimaryCareContracting/ QOF/fs/en (accessed on January 3, 2007).
30. Shibley MC, Pugh CB. Implementation of pharmaceutical care services for patients with hyperlipidemias by independent community pharmacy practitioners. Ann Pharmacother 1997; 31 (6): 713-719.
31. Carter B, Barnette D, Chrischilles E et al. Evaluation of hypertensive patients after care provided by community pharmacists in a rural setting. Pharmacotherapy 1997; 17 (6): 1274-1285.
32. Blenkinsopp A, Phelan M, Bourne J, Dakhil N. Extended adherence support by community pharmacists for patients with hypertension: A randomised controlled trial. Int J Pharm Pract 2000; 8: 165-175.
33. Pharmaceutical Services Negotiating Committee (PSNC). http://www.psnc.org.uk. (accessed on September 9, 2005).
34. Eaton G, Webb B. Boundary encroachment: Pharmacists in the clinical setting. Sociol Health Illn 1979; 1 (1): 69-89.
35. Howard M, Trim K, Woodward C et al. Collaboration between community pharmacists and family physicians: Lessons learned from the seniors medication assessment research trial. J Am Pharm Assoc 2003; 43 (5): 566-572.
36. Effective Health Care: Getting evidence into practice, Effective Health Care Bulletin, 1999; 15(1).
37. Bellingham C. Opportunities in the new GP contract. Pharm J 2004; 272: 240.